Envista Holdings Co. (NYSE:NVST) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lessened its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 96.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,300 shares of the company’s stock after selling 897,300 shares during the quarter. Handelsbanken Fonder AB’s holdings in Envista were worth $681,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Headinvest LLC acquired a new stake in shares of Envista during the third quarter worth approximately $28,000. Fifth Third Bancorp grew its holdings in Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after acquiring an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Envista in the 3rd quarter worth about $47,000. Signaturefd LLC raised its stake in shares of Envista by 1,297.9% in the 4th quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock valued at $63,000 after purchasing an additional 2,427 shares in the last quarter. Finally, Covestor Ltd lifted its position in shares of Envista by 33.9% during the third quarter. Covestor Ltd now owns 2,462 shares of the company’s stock worth $69,000 after purchasing an additional 624 shares during the last quarter.

Analyst Ratings Changes

Several analysts recently weighed in on NVST shares. Jefferies Financial Group lowered Envista from a “buy” rating to a “hold” rating and lowered their price objective for the company from $30.00 to $23.00 in a report on Friday, February 9th. UBS Group began coverage on Envista in a research note on Friday, January 5th. They set a “neutral” rating and a $26.00 price objective on the stock. Leerink Partnrs reiterated an “underperform” rating on shares of Envista in a research note on Monday, February 26th. Morgan Stanley downgraded shares of Envista from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $33.00 to $21.00 in a research report on Friday. Finally, TheStreet lowered shares of Envista from a “c” rating to a “d+” rating in a research note on Wednesday, February 7th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Envista has an average rating of “Hold” and a consensus price target of $27.90.

Envista Stock Up 1.1 %

NVST opened at $20.62 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.23 and a quick ratio of 1.90. Envista Holdings Co. has a 12 month low of $18.95 and a 12 month high of $38.63. The stock’s 50 day moving average price is $20.92 and its 200 day moving average price is $22.65. The stock has a market cap of $3.54 billion, a P/E ratio of -33.80, a P/E/G ratio of 3.81 and a beta of 1.35.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 7th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). The company had revenue of $645.60 million during the quarter, compared to the consensus estimate of $638.37 million. Envista had a negative net margin of 3.90% and a positive return on equity of 6.31%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.52 EPS. As a group, research analysts predict that Envista Holdings Co. will post 1.43 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.